Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
OMEROS CORP director Diana T. Perkinson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The option grant will fully vest and become exercisable on the day before the 2027 annual shareholder meeting, as long as she continues serving as a director through that date. Following this award, she holds 15,000 stock options directly.
OMEROS CORP director Leroy E. Hood received a routine stock option grant as part of non-employee director compensation. He was granted options to buy 15,000 shares of common stock at an exercise price of $10.28 per share, expiring on June 17, 2036. The option will fully vest and become exercisable on the day before the 2027 annual meeting of shareholders, provided he continues to serve as a director through that date.
Omeros Corporation director Arnold C. Hanish received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The options will fully vest and become exercisable on the day before the 2027 annual shareholder meeting, as long as Hanish continues to serve as a director through that date. After this grant, he holds 15,000 stock options directly.
Omeros Corporation director Peter A. Demopulos received a grant of stock options to buy 15,000 shares of common stock at an exercise price of $10.28 per share. The options were awarded under the company’s non-employee director compensation policy and will fully vest the day before the 2027 annual shareholder meeting if he continues serving as a director.
OMEROS CORP director Thomas J. Cable received a grant of stock options covering 15,000 shares of common stock as board compensation. The options were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The options have an exercise price of $10.28 per share and will fully vest on the day before the 2027 annual shareholder meeting, as long as Cable continues to serve as a director through that date. After this grant, he holds 15,000 stock options directly.
Omeros Corp director Thomas F. Bumol received a grant of stock options covering 15,000 shares of common stock as part of the company’s non-employee director compensation policy. The options have an exercise price of $10.28 per share and expire on June 17, 2036.
The award relates to the annual meeting of shareholders held on June 18, 2026. The option will fully vest and become exercisable on the day before the 2027 annual meeting of shareholders, provided he continues to serve as a director through that date.
Omeros Corporation entered into privately negotiated agreements to repurchase up to approximately $16.0 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029. The total purchase price, including accrued and unpaid interest and all other obligations, will be up to approximately $34.0 million, subject to adjustment based on the trading price of its common stock during an averaging period beginning on June 18, 2026.
The company expects these repurchases to close between July 6, 2026 and July 16, 2026, following completion of the averaging period. If the full $16.0 million principal amount is repurchased, approximately $54.8 million aggregate principal amount of these Notes will remain outstanding.
Omeros Corp director Thomas J. Cable executed an options exercise-and-sale transaction involving 7,500 shares of common stock. He exercised stock options to acquire 7,500 shares at $10.84 per share, then sold 7,500 shares in open-market trades at a weighted average price of $11.6052 per share.
The sales were made pursuant to a previously established Rule 10b5-1 trading plan adopted on June 14, 2024, with the trading schedule set at that time. Following these transactions, Cable directly holds 35,067 shares of Omeros common stock. The options exercised were scheduled to expire on June 9, 2026, and the sale trades ranged in price from $11.46 to $11.93 per share.
Omeros Corporation reported a sharp turnaround in Q1 2026, posting net income of $56.1 million versus a $33.5 million loss a year earlier. The improvement was largely due to a $73.1 million non-cash gain from remeasuring the embedded derivative on its 2029 convertible notes.
Product sales reached $9.9 million following the January 2026 U.S. launch of YARTEMLEA for TA-TMA, while research and development spending declined to $13.4 million from $23.8 million. Operating cash flow remained negative at $14.5 million, but Omeros held $1.9 million in cash and $133.4 million in short-term investments as of March 31, 2026.
The balance sheet shows a shareholders’ deficit of $63.3 million, improved from $121.2 million at year-end 2025, influenced by the zaltenibart sale and debt actions. The company also continues to recognize income from OMIDRIA royalties and retains significant potential milestones and royalties from its APLA with Novo Nordisk.